IFNL3 and coinfection: The log-rank analysis revealed no significant differences in the time to achieve optimum viral load suppression across sex (p = 0.223), age groups (p = 0.358), HCV genotypes (p = 0.083), IL-28B genotypes (p = 0.342), the presence of HIV coinfection (p = 0.565), previous interferon treatment exposure (p = 0.158), injection drug use (p = 0.518), the use of concomitant medications (p = 0.121), or the presence of comorbidities (p = 0.666).